“A New Alzheimer’s Disease Treatment Shows Promise: 35% Reduction in Cognitive Decline”

A new treatment for Alzheimer’s disease shows promise. Produced by Eli Lilly, the treatment demonstrated, in a large-scale clinical study, that it slows down the cognitive decline associated with the disease.

The results of this new treatment were enthusiastically received by experts, who welcomed the entry into a “new era” in the management of Alzheimer’s disease, thanks to several recent discoveries, Adevărul reports.

The clinical trial, which included 1,200 participants who had not yet reached an advanced stage of the disease, showed a 35 percent reduction in cognitive decline in patients treated with donanemab, according to a company release.

Eli Lilly plans to submit an application to the US Food and Drug Administration (FDA) as early as this quarter and worldwide “as soon as possible.”

However, the treatment can have serious side effects, such as cerebral edema or haemorrhages. Three participants in the clinical trial died.

Cognitive decline, reduced by 40%

The clinical trial also measured the ability to perform daily tasks such as driving, conversation, leisure activities or managing finances. During 18 months, the participants who received the treatment showed a 40% reduction in the decline of their ability to perform these tasks, according to sources cited by Agerpres.

“These results confirm that we are entering the era of treatment for Alzheimer’s disease,” enthused Catherine Mummery from the National Hospital for Neurology and Neurosurgery in London.

It will now be possible “to realistically expect to be able to treat and stabilize a person with Alzheimer’s disease through long-term management rather than palliative and supportive care,” she added.

Research into the fight against Alzheimer’s has stagnated for decades.

However, two new treatments, developed by Japanese (Eisai) and US (Biogen) pharmaceutical companies, have recently been approved in the US: Leqembi (whose active ingredient is called lecanemab) and Aduhelm (which uses a molecule called aducanumab). .

Several treatment options

While the approval of Aduhelm was controversial, with some experts pointing out the lack of evidence regarding its effectiveness, lecanemab was the first to demonstrate that it reduced cognitive decline (by 27%) in a clinical trial.

Eli Lilly’s treatment, if “approved in the same way as lecanemab”, could “give patients the opportunity to choose between more treatments”, said Liz Coulthard from the University of Bristol.

Alzheimer’s disease affects tens of millions of people worldwide.

You found out that